NAS10030,808+1.00%S&P7,723+0.73%GOLD$4,196+0.81%BTC$86,156−0.37%VIX16.35+6.79%live tape · as of 09:01 UTC
The Screen · Healthcare · Medical Devices
Senseonics Holdings Inc
SENS · NASDAQ · USD · Market cap $267M · 130 employees
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
FAIL · Does not pass the screen
9.58 USD
Screen close, 2026-09-18 · not a live quote Last reviewed 17 days ago
Screened 2026-09-18 · the tape above runs as of 09:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 9.58 against the desk's fair-value range, base estimate 14.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price9.58 USD
Fair value14.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-12Read Accumulation5.11+87.5% to today ✓
2026-08-12Read Distribution5.11+87.5% to today
2026-07-02Read Markup7.18+33.4% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Senseonics Holdings Inc holds its Accumulation at $9.58. Consolidating, no directional conviction, held for 3 days.
As held on the ledger · 2026-09-18
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 3 days
Price at the screen
$9.58
Valuation
N/A trailing · -2.33 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.99
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
32.76%
Below 33%
Interest-bearing debt is just 32.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
42.60%
Below 33%
Interest-bearing cash and securities are 42.6% of assets, above the one-third limit.
Fail
Receivables
41.46%
Below 49%
Money owed to the company is 41.5% of assets, under the 49% limit.
Pass
Revenue purity
11.91%
Below 5%
11.9% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Senseonics's business is fine, but its cash and interest-bearing securities are about 43% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-18 screen. The gold marker is the market price at the same screen. A 46.1% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus Buy. The average target sits +46% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SENS trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Accumulation$9.58+87.5%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 87.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (5 analysts) rates it buy, with a mean price target of $14.
2026-09-12Accumulation · changed$5.11+0.0%Entry 5
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (5 analysts) rates it buy, with a mean price target of $14.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 28.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (5 analysts) rates it buy, with a mean price target of $14.
2026-07-18Markup$7.18+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (5 analysts) rates it buy, with a mean price target of $14.
2026-07-03Markup$7.18+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$7.18Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.